{
    "clinical_study": {
        "@rank": "35261", 
        "arm_group": [
            {
                "arm_group_label": "auto", 
                "arm_group_type": "Active Comparator", 
                "description": "patients receive autologous SCT"
            }, 
            {
                "arm_group_label": "haplo", 
                "arm_group_type": "Active Comparator", 
                "description": "patients receive haplo-SCT"
            }
        ], 
        "brief_summary": {
            "textblock": "A multicentre, prospective, open-label clinical study, including a randomized controlled\n      study in low or intermediate-risk group patients, and a cohort study of maintenance\n      treatment with decitabine after ASCT."
        }, 
        "brief_title": "Haplo-SCT vs ASCT With or Without Decitabine in AML CR1", 
        "completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Myeloid Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age >= 18y\n\n          -  Diagnosed as AML (except acute promyelocytic leukemia M3) for the first time\n\n          -  Minimal Residual Disease (MRD) test can be achieved (molecular biology first if\n             applicatable, and/or cytogenetics and/or immunophenotyping)\n\n          -  Presence of an available haplo-mismatch related donor\n\n        Exclusion Criteria:\n\n          -  Contra-indications of chemotherapy or  hematopoietic stem cell transplantation\n\n          -  Presence of an available identical sibling donor or a 10/10 HLA loci-matched\n             unrelated donor\n\n          -  Participating in other clinical trials concerning the prophylaxis of disease\n             recurrence after ASCT\n\n          -  No effective contraception\n\n          -  Pregnant or lactating females\n\n          -  Other causes which are not suitable for the trial in investigator's consideration"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "212", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02059720", 
            "org_study_id": "SZ3702", 
            "secondary_id": "ChiCTR-TRC-14004196"
        }, 
        "intervention": {
            "arm_group_label": [
                "auto", 
                "haplo"
            ], 
            "description": "Patients randomly assigned in to either of  groups will receive either autologous SCT or haplo-SCT after CR1 is achieved.", 
            "intervention_name": "HSCT", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "acute myeloid leukemia", 
            "allogeneic hematopoietic stem cell transplantation", 
            "autologous hematopoietic stem cell transplantation", 
            "maintenance treatment", 
            "hematopoietic stem cell transplantation"
        ], 
        "lastchanged_date": "February 10, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Suzhou", 
                    "country": "China", 
                    "state": "Jiangsu", 
                    "zip": "215006"
                }, 
                "name": "The Fisrt Affiliated Hospital of Soochow University"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Haplo-mismatch Donor Stem Cell Transplantation (SCT) Versus Autologous SCT Followed or Not by Maintenance Therapy, for Patients With Acute Myeloid Leukemia (AML) in First Remission: A Chinese Randomized Multicenter Study", 
        "other_outcome": {
            "description": "Including incidence and severity of acute and chronic GVHD, activity of daily living, psychological status, recovery of professional activity, social adaption, etc.", 
            "measure": "Quality of Life", 
            "safety_issue": "Yes", 
            "time_frame": "Five years"
        }, 
        "overall_official": {
            "affiliation": "The First Affiliated Hospital of Soochow University", 
            "last_name": "Depei Wu, M.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Defined as the survival duration starting at the day of graft infusion, terminating at the day of death, morphological relapse or the end of follow-up.", 
            "measure": "Leukemia-Free Survival", 
            "safety_issue": "Yes", 
            "time_frame": "Five years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02059720"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Defined as the survival duration starting at the day of graft infusion, terminating at the day of death or the end of follow-up.", 
                "measure": "Overall survival", 
                "safety_issue": "Yes", 
                "time_frame": "Five years"
            }, 
            {
                "description": "Defined as the cumulative incidence of morphological relapse after the day of graft infusion.", 
                "measure": "Cumulative relapse incidence", 
                "safety_issue": "No", 
                "time_frame": "Five years"
            }, 
            {
                "description": "Defined as the cumulative incidence of death without cause of disease recurrence, which include the cause of GVHD, infection, hemorrhage, organic function failure, etc.", 
                "measure": "Non-relapse Mortality", 
                "safety_issue": "Yes", 
                "time_frame": "Five years"
            }, 
            {
                "description": "Defined as the cumulative incidence of durable complete donor chimerism detected by STR-PCR.", 
                "measure": "Cumulative incidence of engraftment", 
                "safety_issue": "No", 
                "time_frame": "180 days"
            }
        ], 
        "source": "The First Affiliated Hospital of Soochow University", 
        "sponsors": {
            "collaborator": {
                "agency": "European Group for Blood and Marrow Transplantation", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "The First Affiliated Hospital of Soochow University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}